Cencora, Inc. (COR) is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern.Shares of this Zacks Rank #2 (Buy) company have risen 10.8% in the past six months against the industry’s 11% decline. The S&P 500 Index has increased 12.3% in the same time frame.Cencora is one of the world’s largest pharmaceutical service companies. It is focused on providing drug distribution and related services to reduce healthcare costs ...

Viking Therapeutics (VKTX) is set to report fourth-quarter and full-year 2024 earnings on Feb. 5, after market close. Since the company lacks a marketed drug in its portfolio, we do not expect it to record revenues. The Zacks Consensus Estimate for earnings is pegged at a loss of 27 cents per share. Estimates for 2025 loss per share have improved slightly from $1.42 to $1.41 in the past 60 days.See the Zacks Earnings Calendar to stay ahead of market-making news. Image Source: Zacks Investment ResearchVKTX’s ...

SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today issued the following statement in response to the Patent Trial and Appeal Board's (PTAB) final written decision in PGR2023-00043 regarding U.S. Patent No. 11,572,334 (the "'334 patent"). Atossa is disappointed with the PTAB's decision finding all challenged claims in the '334 patent unpaten ...

SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today issued the following statement in response to the Patent Trial and Appeal Board’s (PTAB) final written decision in PGR2023-00043 regarding U.S. Patent No. 11,572,334 (the “’334 patent”). Atossa is disappointed with the PTAB’s decision finding all challenged claims in the ’334 patent unpate ...

Atmos Energy Corporation (ATO) is scheduled to release first-quarter fiscal 2025 results on Feb. 4, after market close. The company delivered an earnings surprise of 2.4% in the last reported quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.Let’s discuss the factors that are likely to be reflected in the upcoming quarterly results.Key Factors That Might Have Impacted ATO Stocks' Q1 EarningsAtmos Energy continues to benefit from strategic investments and its focus on modernizing th ...

Calumet, Inc. (CLMT) shares soared 12.1% in the last trading session to close at $16.83. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 31.8% loss over the past four weeks.The bullishness can be attributed to the strong demand for Calumet’s specialty products and renewable fuels. The company’s diverse portfolio, which includes base oils, specialty oils, waxes, and fuels, continues to meet and exceed customer expectations. CLMT's ...

Cigna (CI) came out with quarterly earnings of $6.64 per share, missing the Zacks Consensus Estimate of $7.83 per share. This compares to earnings of $6.79 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -15.20%. A quarter ago, it was expected that this health insurer would post earnings of $7.22 per share when it actually produced earnings of $7.51, delivering a surprise of 4.02%.Over the last four quarters, the company has s ...

Trane Technologies (TT) came out with quarterly earnings of $2.61 per share, beating the Zacks Consensus Estimate of $2.54 per share. This compares to earnings of $2.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.76%. A quarter ago, it was expected that this manufacturer would post earnings of $3.23 per share when it actually produced earnings of $3.37, delivering a surprise of 4.33%.Over the last four quarters, the comp ...

Flagstar Financial (FLG) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.81 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 32%. A quarter ago, it was expected that this bank holding company would post a loss of $0.40 per share when it actually produced a loss of $0.69, delivering a surprise of -72.50%.Over the last four quarters, the company ...

Earnings Call Overview - Nokia held its Q4 2024 earnings conference call on January 30, 2025, with key participants including President and CEO Pekka Lundmark and CFO Marco Wiren [1][2] - The call included forward-looking statements regarding future business, transactions, and financial performance, with actual results subject to risks and uncertainties [3] - Growth rates and margins discussed during the call were based on constant currency and comparable reporting, with detailed financial results available in the Q4 report on the company's website [4] Call Agenda - Pekka Lundmark will present key messages for the quarter, followed by Marco Wiren discussing financial performance [5] - Pekka Lundmark will also highlight specific achievements or notable developments from the quarter [5]